Global Information
회사소개 | 문의

신경보호제 : 치료 용도 및 세계 시장

Neuroprotective Agents: Therapeutic Applications and Global Markets

리서치사 BCC Research
발행일 2018년 06월 상품 코드 648089
페이지 정보 영문 133 Pages
가격
US $ 4,950 ₩ 5,659,800 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,940 ₩ 6,791,700 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,128 ₩ 8,150,100 PDF by E-mail (Site License)
US $ 8,554 ₩ 9,780,600 PDF by E-mail (Enterprise License)


신경보호제 : 치료 용도 및 세계 시장 Neuroprotective Agents: Therapeutic Applications and Global Markets
발행일 : 2018년 06월 페이지 정보 : 영문 133 Pages

한글목차

세계의 신경보호제 시장 규모는 2017-2022년의 예측기간 중 6.8%의 연평균 성장률(CAGR)로 성장하여 2017년 544억 달러에서 2022년에는 758억 달러 규모로 확대될 전망입니다.

세계의 신경보호제(Neuroprotective Agents) 시장에 대해 조사했으며, 시장 개요, 시장 및 기술 배경, 기술 유형·치료 지표·지역별 동향, 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 서론

제2장 요약과 하이라이트

제3장 시장 및 기술 배경

  • 신경보호
    • 신경보호 치료가 요구되는 이유는?
    • 신경보호 전략
  • 뇌혈관질환
    • 뇌졸중
    • 뇌졸중의 신경보호
  • 신경변성질환
    • 파킨슨병
    • ALS(루게릭병)
    • 다발성 경화증
    • 알츠하이머병
    • 헌팅턴병
    • 척수성 근위축증(SMA)
    • 간질
    • 신경변성질환의 신경보호
  • 안질환
    • 녹내장
    • 비동맥 전방허혈성 시신경증(NAION)
    • 노인성 황반변성(AMD)
    • 당뇨망막병증
    • 안질환의 신경보호
  • 외상성 CNS(중추신경계) 손상
    • 외상성 뇌손상
    • 외상성 척수손상
    • 외상성 CNS(중추신경계) 손상의 신경보호

제4장 시장 분석 : 기술 유형별

  • 치료제
  • 재생 의료 제품

제5장 시장 분석 : 치료 지표별

  • 심혈관질환
  • 신경변성질환
  • 안질환
  • 외상성 CNS(중추신경계) 손상

제6장 시장 분석 : 지역별

제7장 기업 개요

BCC Research 소개

KSM 18.06.14

List of Tables

  • Summary Table: Global Market for Neuroprotective Agents, by Region, Through 2022 ($ Millions)
    • Table 1: Global Market for Neuroprotective Agents, by Technology Type, Through 2022 ($ Millions)
    • Table 2: Global Market for Neuroprotective Agents, by Application, Through 2022 ($ Millions)
    • Table 3: Global Market for Therapeutic Agents, by Drug Class, Through 2022 ($ Millions)
    • Table 4: Global Market for Antisense Agents, Through 2022 ($ Millions)
    • Table 5: Global Market for Anti-Amyloid Agents, Through 2022 ($ Millions)
    • Table 6: Neuroprotective Interferons Available in Global Markets, by Brand
    • Table 7: Neuroprotective Monoclonal Antibodies Available in Global Markets, by Brand
    • Table 8: Key Immune Response Modifiers in Clinical Development
    • Table 9: Global Market for Immune Response Modifiers, Through 2022 ($ Millions)
    • Table 10: Key Antioxidants in Clinical Development
    • Table 11: Global Market for Antioxidants, Through 2022 ($ Millions)
    • Table 12: Key Anti-angiogenic Agents in Clinical Development
    • Table 13: Global Market for Anti-Angiogenic Agents, Through 2022 ($ Millions)
    • Table 14: Global Market for Anti-Parkinson's Agents, Through 2022 ($ Millions)
    • Table 15: Key Anticonvulsants in Clinical Development
    • Table 16: Global Market for Anticonvulsants, Through 2022 ($ Millions)
    • Table 17: Global Market for Ocular Hypotensives, Through 2022 ($ Millions)
    • Table 18: Global Market for Thrombolytics, Through 2022 ($ Millions)
    • Table 19: Global Market for Blood Thinning Agents, Through 2022 ($ Millions)
    • Table 20: Global Market for Anti-Dementia Agents, Through 2022 ($ Millions)
    • Table 21: Key Neuroprotective Drug Candidates with Novel MoA in Clinical Development
    • Table 22: Global Market for Other Neuroprotective Agents, Through 2022 ($ Millions)
    • Table 23: Global Market for Regenerative Medicine Products, Through 2022 ($ Millions)
    • Table 24: Global Market Share for Key Players in Neuroprotection, 2017 (%)
    • Table 25: Global Market for Neuroprotective Agents, by Therapeutic Indication, Through 2022 ($ Millions)
    • Table 26: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, Through 2022 ($ Millions)
    • Table 27: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, Type, Through 2022 ($ Millions)
    • Table 28: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, Through 2022 ($ Millions)
    • Table 29: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, Through 2022 ($ Millions)
    • Table 30: Global Market for Neuroprotective Agents, by Region, Through 2022 ($ Millions)
    • Table 31: North American Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 32: European Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 33: Asia-Pacific Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 34: ROW Market for Neuroprotective Agents, by Indication, Through 2022 ($ Millions)
    • Table 35: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, Through 2022 ($ Millions)
    • Table 36: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, Region, Through 2022 ($ Millions)
    • Table 37: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, Through 2022 ($ Millions)
    • Table 38: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, Through 2022 ($ Millions)

List of Figures

  • Summary Figure: Global Market for Neuroprotective Agents, by Region, 2016-2022 ($ Millions)
    • Figure 1: Global Market for Neuroprotective Agents, by Technology Type, 2016-2022 ($ Millions)
    • Figure 2: Global Market for Neuroprotective Agents, by Application, 2016-2022 ($ Millions)
    • Figure 3: Global Market for Therapeutic Agents, by Drug Class, 2016-2022 ($ Millions)
    • Figure 4: Global Market for Antisense Agents, 2016-2022 ($ Millions)
    • Figure 5: Global Market for Anti-Amyloid Agents, 2016-2022 ($ Millions)
    • Figure 6: Global Market for Immune Response Modifiers, 2016-2022 ($ Millions)
    • Figure 7: Global Market for Antioxidants, 2016-2022 ($ Millions)
    • Figure 8: Global Market for Anti-Angiogenic Agents, 2016-2022 ($ Millions)
    • Figure 9: Global Market for Anti-Parkinson's Agents, 2016-2022 ($ Millions)
    • Figure 10: Global Market for Anticonvulsants, 2016-2022 ($ Millions)
    • Figure 11: Global Market for Ocular Hypotensives, 2016-2022 ($ Millions)
    • Figure 12: Global Market for Thrombolytics, 2016-2022 ($ Millions)
    • Figure 13: Global Market for Blood Thinning Agents, 2016-2022 ($ Millions)
    • Figure 14: Global Market for Anti-Dementia Agents, 2016-2022 ($ Millions)
    • Figure 15: Global Market for Other Neuroprotective Agents, 2016-2022 ($ Millions)
    • Figure 16: Global Market for Regenerative Medicine Products, 2016-2022 ($ Millions)
    • Figure 17: Global Market Share for Key Players in Neuroprotection, 2017 (%)
    • Figure 18: Global Market for Neuroprotective Agents, by Therapeutic Indication, 2016-2022 ($ Millions)
    • Figure 19: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, 2016- 2022 ($ Millions)
    • Figure 20: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Type, 2017-2022 ($ Millions)
    • Figure 21: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Type, 2016-2022 ($ Millions)
    • Figure 22: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Type, 2016-2022 ($ Millions)
    • Figure 23: Global Market for Neuroprotective Agents, by Region, 2016-2022 ($ Millions)
    • Figure 24: North American Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 25: European Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 26: Asia-Pacific Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 27: ROW Market for Neuroprotective Agents, by Indication, 2016-2022 ($ Millions)
    • Figure 28: Global Market for Neuroprotective Agents Used in Treating Cerebrovascular Disease, by Region, 2016-2022 ($ Millions)
    • Figure 29: Global Market for Neuroprotective Agents Used in Treating Neurodegenerative Disorders, by Region, 2016-2022 ($ Millions)
    • Figure 30: Global Market for Neuroprotective Agents Used in Treating Ophthalmic Diseases, by Region, 2016-2022 ($ Millions)
    • Figure 31: Global Market for Neuroprotective Agents Used in Treating Traumatic CNS Injuries, by Region, 2016-2022 ($ Millions)

영문목차

Report Highlights

The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.

Report Includes:

  • 39 tables
  • An overview of the global market for neuroprotective agents and their therapeutic applications
  • Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Market breakdowns by indication, mechanism of action, and by region
  • Introduction of breakthrough biomarker studies that assist in neuroprotection
  • Discussion of various neurodegenarative disorders
  • Profiles of key companies in the market, including Bayer Healthcare, Eisai Inc., Glaxosmithkline Plc, Merck Serono S.A., Novartis Ag and Teva Pharmaceutical Industries Ltd.

Report Scope

The scope of this report covers the global market for small molecule drugs, monoclonal antibodies, gene and cell therapies, and other biotechnology products that are approved or being developed for the treatment of neurological disorders.

Therapeutic indications are grouped under four categories: cerebrovascular diseases, neurodegenerative disorders, ophthalmic diseases and traumatic CNS injuries. Indication subcategories include stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, spinal muscular atrophy, epilepsy, glaucoma, age-related macular degeneration, optic neuropathies, diabetic retinopathy and traumatic brain and spinal cord injuries. The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.

Analyst Credentials

Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Neuroprotection
    • Why Are Neuroprotective Therapies Needed?
    • Neuroprotective Strategies
  • Cerebrovascular Disease
    • Stroke
    • Neuroprotection in Stroke
  • Neurodegenerative Disorders
    • Parkinson's Disease
    • Amyotrophic Lateral Sclerosis
    • Multiple Sclerosis
    • Alzheimer's Disease
    • Huntington's Disease
    • Spinal Muscular Atrophy
    • Epilepsy
    • Neuroprotection in Neurodegenerative Disorders
  • Ophthalmic Diseases
    • Glaucoma
    • Nonarteritic Anterior Ischemic Optic Neuropathy
    • Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Neuroprotection in Ophthalmic Diseases
  • Traumatic CNS Injuries
    • Traumatic Brain Injury
    • Traumatic Spinal Cord Injuries
    • Neuroprotection in Traumatic CNS Injuries

Chapter 4: Market Breakdown by Technology Type

  • Therapeutic Agents
    • Antisense Agents
    • Anti-amyloid Agents
    • Immune Response Modifiers
    • Antioxidants
    • Anti-angiogenic Agents
    • Anti-Parkinson's Agents
    • Anticonvulsants
    • Ocular Hypotensives
    • Thrombolytics
    • Blood Thinning Agents
    • Anti-dementia Agents
    • Other Neuroprotective Agents
  • Regenerative Medicine Products
    • Brainstorm Cell Therapeutics' Nurown as First ALS Cell Therapy in the U.S.
    • Neuronata-R to Expand to International ALS Markets
    • Multistem Fast-tracked for Ischemic Stroke
    • CEVA101 Advances in Traumatic Brain Injury Trials
    • Asterias Biotherapeutics Snatches RMAT for Spinal Cord Injuries
    • CTX0E03 Advances in PISCES II Trials for Stroke Disability

Chapter 5: Market Breakdown by Therapeutic Indication

  • Neuroprotective Agents for Cerebrovascular Disease
  • Neuroprotective Agents for Neurodegenerative Disorders
  • Neuroprotective Agents for Ophthalmic Diseases
  • Neuroprotective Agents for Traumatic Central Nervous System Injuries

Chapter 6: Market Breakdown by Region

Chapter 7: Company Profiles

About BCC Research

  • About BCC Research
  • BCC Library Access
  • BCC Custom Research
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research